ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1367

Clinical Features and Treatment Results of Japanese Patients with SAPHO (Synovitis-Acne-Pustulosis-Hyperostosis-Osteitis) Syndrome

Hiroki Yabe1, Takashi Kuroiwa1, Aya Nonaka1, Tomomi Tsutsumi1, Tadashi Sakurai1, Masato Moriguchi1, Hisaji Oshima2, Kensuke Ochi3 and Chihiro Terai1, 1Division of Rheumatology, Jichi Medical University Saitama Medeical Center, Saitama City, Japan, 2Connective Tissue Diseases, Tokyo Medical Ctr, Tokyo, Japan, 3Department of Orthopaedic Surgery, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Clinical, human leukocyte antigens (HLA) and treatment, SAPHO syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment

Session Type: Abstract Submissions (ACR)

Background/Purpose: SAPHO syndrome is a disorder characterized by pustular skin lesions and osteoarticular lesions, which was proposed by Chamot et al. in 1987. Clinical studies based on the diagnostic criteria of SAPHO syndrome are mainly reported from Europe, and still limited in East-Asia.

Methods: We investigated the clinical features and treatment results in 31 Japanese patients with SAPHO syndrome (male 10, female 21) diagnosed and treated between 2003 and 2011. HLA-A and -B typing was performed in 30 patients, and their allele frequencies were compared with those in the healthy Japanese controls, using Fisher’s exact test.

Results: The age at onset was ranged between 16 and 68 years old (y.o.) (average: 48.3), and the age at diagnosis from 16 to 74 y.o. (average: 53.8). The average follow-up period was 42 months. Sternocostoclavicular hyperostosis was the main manifestation and recognized in 29 cases (94%). Pustular dermatitis including palmoplantar pustulosis  was seen in 26 cases (84%). As other manifestations, recurrent oral ulceration was seen in 6 cases (19%), and inflammatory bowel disease in 2 cases. Most patients had intermittent attacks of pain, therefore oral NSAIDs were needed in all cases and oral prednisolone (PSL) in 14 cases (45%). The oral NSAIDs and/or PSLwere effective for temporary pain relief. DMARDs (SSZ and/or MTX) were used in 14 cases (45%) with recurrent chronic pain. Pain relief more than 50% was seen in only 4 cases (29%) out of DMARDs users. In two refractory cases with severe spondylitis, adalimumab (ADA) was tried. Both cases showed immediate pain-relief and ADA was effective during at least one year. HLA tests revealed that the allele frequencies of HLA-B27 and HLA-B51were respectively 0% and 12%, which were similar with those in healthy Japanese controls. On the other hand, the frequency of HLA-B61 was 27 % and significantly higher than that (12%) in healthy controls.

Conclusion: Mucosal lesions seem to be a rather frequent complication of SAPHO syndrome in our study. The efficacy of DMARDs (SSZ and/or MTX) was observed in a small number of patients. ADA was effective in two refractory cases with severe spondylitis. This study revealed that HLA-B61 was significantly increased in Japanese patients with SAPHO syndrome.


Disclosure:

H. Yabe,
None;

T. Kuroiwa,
None;

A. Nonaka,
None;

T. Tsutsumi,
None;

T. Sakurai,
None;

M. Moriguchi,
None;

H. Oshima,
None;

K. Ochi,
None;

C. Terai,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-features-and-treatment-results-of-japanese-patients-with-sapho-synovitis-acne-pustulosis-hyperostosis-osteitis-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology